Comparative Pharmacology
Head-to-head clinical analysis: DROXIDOPA versus LEVOPHED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROXIDOPA versus LEVOPHED.
DROXIDOPA vs LEVOPHED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Droxidopa is a synthetic precursor of norepinephrine that increases norepinephrine levels in the peripheral nervous system, thereby improving sympathetic tone and blood pressure regulation.
Norepinephrine acts predominantly on alpha-1 adrenergic receptors to cause vasoconstriction and increase blood pressure. It also has beta-1 adrenergic receptor agonist activity, resulting in positive inotropic effects on the heart.
100-200 mg orally three times daily, with a maximum of 600 mg three times daily if needed.
Initial dose: 8-12 mcg/min intravenously, titrate to desired blood pressure; typical maintenance: 2-4 mcg/min IV continuous infusion.
None Documented
None Documented
Clinical Note
moderateDroxidopa + Torasemide
"Droxidopa may increase the hypokalemic activities of Torasemide."
Clinical Note
moderateDroxidopa + Etacrynic acid
"Droxidopa may increase the hypokalemic activities of Etacrynic acid."
Clinical Note
moderateDroxidopa + Furosemide
"Droxidopa may increase the hypokalemic activities of Furosemide."
Clinical Note
moderateDroxidopa + Bumetanide
"Droxidopa may increase the hypokalemic activities of Bumetanide."
2–3 hours; terminal half-life approximately 2.5 hours, requiring 3–4 times daily dosing to maintain plasma levels.
The terminal elimination half-life is approximately 2 minutes. The clinical effect is short-lived due to rapid reuptake and metabolism; continuous intravenous infusion is required for sustained effect.
Renal: ~75% as unchanged drug and metabolites (including 3-O-methyldroxidopa and other conjugates); biliary/fecal: minimal (<5%).
Norepinephrine is primarily metabolized in the liver and other tissues by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). Less than 5% is excreted unchanged in urine. Metabolites are excreted renally (approximately 80-95% as normetanephrine, vanillylmandelic acid, and other conjugates).
Category C
Category C
Vasopressor
Vasopressor